A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

This Phase 1 trial is testing a new experimental cancer drug called CTX-8371 in people with advanced cancers that have not responded to prior immunotherapy. CTX-8371 is a new type of immune therapy that works differently from standard checkpoint inhibitors. The study is focused on several cancer types including melanoma, head and neck cancer, lung cancer, triple-negative breast cancer, and Hodgkin lymphoma. **You may be eligible if...** - You are 18 or older with advanced cancer (melanoma, head/neck squamous cell carcinoma, non-small cell lung cancer, triple-negative breast cancer, or classical Hodgkin lymphoma) that has not responded to prior treatment including immunotherapy - You have previously received at least 2 doses of a PD-1/PD-L1 inhibitor (a type of immunotherapy) and your cancer has progressed - You are in good health (ECOG 0–1) with adequate organ function - Your last immunotherapy was within 12 weeks of enrolling **You may NOT be eligible if...** - You had to permanently stop immunotherapy due to severe immune-related side effects - You have brain metastases (cancer that spread to the brain) - You have had a prior organ transplant - You have an active autoimmune disease requiring high-dose steroids - You have significant uncontrolled heart disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.